155 related articles for article (PubMed ID: 2435122)
1. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia.
Stahl F; Schnorr D; Rohde W; Poppe I; Geier T; Dörner G
Exp Clin Endocrinol; 1983 Jul; 82(1):21-8. PubMed ID: 6193975
[TBL] [Abstract][Full Text] [Related]
3. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
5. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
Bartsch G; Oberholzer M; Rohr HP
Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
[TBL] [Abstract][Full Text] [Related]
6. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
[No Abstract] [Full Text] [Related]
7. Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.
Ortega E; Ruiz E; Mendoza MC; Martin-Andres A; Osorio C
Experientia; 1979 Jun; 35(6):844-5. PubMed ID: 89045
[TBL] [Abstract][Full Text] [Related]
8. [The influence of spironolactone on the concentration of gonadotrophins and gonadal hormones in prostatic hypertrophy (author's transl)].
Zgliczynski S; Baranowska B; Szymanowski J
J Urol (Paris); 1981; 87(9):635-8. PubMed ID: 6174646
[TBL] [Abstract][Full Text] [Related]
9. [Pre- and post-prostatectomy variation and supplement of sexual hormones in patients with benign prostatic hyperplasia].
Ren XM; Ying J; Yao DH; Jiang YQ; Xu MX
Zhonghua Nan Ke Xue; 2005 Jan; 11(1):50-2, 55. PubMed ID: 15704683
[TBL] [Abstract][Full Text] [Related]
10. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
Maleeva A; Tsvetkov M; Kekhaĭova M
Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
[TBL] [Abstract][Full Text] [Related]
11. [Fundamental and clinical study of the anti-prostatic effect of allylestrenol].
Yamanaka H; Kosaku N; Makino T; Shida K
Hinyokika Kiyo; 1983 Sep; 29(9):1133-45. PubMed ID: 6203385
[TBL] [Abstract][Full Text] [Related]
12. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
[No Abstract] [Full Text] [Related]
13. Does erythropoietin cause hormonal changes in haemodialysis patients?
Steffensen G; Aunsholt NA
Nephrol Dial Transplant; 1993; 8(11):1215-8. PubMed ID: 8302458
[TBL] [Abstract][Full Text] [Related]
14. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
15. [Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy].
Umeda K
Hinyokika Kiyo; 1991 Nov; 37(11):1429-33. PubMed ID: 1722628
[TBL] [Abstract][Full Text] [Related]
16. Hormonal status in prostatic disease.
Frick J; Bartsch G
Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
[No Abstract] [Full Text] [Related]
17. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone.
Casarosa C; Cosci di Coscio M; Fratta M
Clin Ther; 1988; 10(5):585-8. PubMed ID: 2485240
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
Baranowska B; Zgliczynski S; Szymanowski J
J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone and gonadotropin-releasing hormone on serum TSH, PRL, hGH, FSH and LH in primary testicular failure and in hypogonadotrophic hypogonadism.
Szilágyi G; Szabolcs I; Vydra G; Góth M; Irsy G
Acta Med Hung; 1984; 41(4):175-83. PubMed ID: 6440114
[TBL] [Abstract][Full Text] [Related]
20. The hormonal status of patients with benign prostatic hypertrophy: FSH, LH, TSH and prolactin responses to releasing hormones.
Hammond GL; Lukkarinen O; Vihko P; Kontturi M; Vihko R
Clin Endocrinol (Oxf); 1979 Jun; 10(6):545-52. PubMed ID: 89919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
